DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Gabapentin on the Sensation and Impact of Tinnitus

Information source: Tinnitus Research Consortium
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Tinnitus

Intervention: gabapentin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Tinnitus Research Consortium

Official(s) and/or principal investigator(s):
Carol Bauer, MD, Principal Investigator, Affiliation: Southern Illinois University School of Medicine

Summary

This study evaluated the effectiveness of gabapentin in treating tinnitus in two populations: Tinnitus with associated acoustic trauma and tinnitus without associated acoustic trauma. The hypothesis was that gabapentin would decrease both subjective and objective features of tinnitus in the trauma group, but would be less effective in the non-trauma group.`

Clinical Details

Official title: The Effect of Gabapentin on the Sensation and Impact of Tinnitus

Study design: Treatment, Non-Randomized, Single Blind, Placebo Control, Crossover Assignment, Efficacy Study

Primary outcome:

Psychophysical loudness match of tinnitus to broad band noise and pure tones.

Subjective evaluation of tinnitus impact using Tinnitus Handicap Questionnaire.

The subjective and objective measures were obtained after treatment with placebo and 4 doses of gabapentin.

Secondary outcome: Quality of Life survey (SF36-QOL)

Detailed description: Methods. A prospective, placebo-controlled, single-blind study of the effect of gabapentin on tinnitus was employed. Audiograms and personal histories were used to categorize tinnitus etiology as either secondary to acoustic trauma, or not associated with acoustic trauma. Participants were restricted to those with moderate-to-severe tinnitus for at least one year. All participants received gabapentin in a graduated ascending-descending dose series over 20 weeks (peak dose of 2400 mg/day).

Results. There was a significant improvement in tinnitus annoyance for the trauma group (p = 0. 05). Other subjective aspects of tinnitus were not significantly affected in either group. Between-subject variability of therapeutic response was considerable. Nevertheless, considering subjective loudness ratings, 4/19 non-trauma participants, and 6/20 trauma participants showed an improvement of 20 percent or better. Considering psychoacoustic loudness estimates, 4/19 non-trauma and 6/20 trauma participants showed a 15 dB (HL) improvement. Evenly dividing each group into high and low responders revealed significant improvement in loudness at 1800 and 2400 mg/day for the trauma high-response subgroup (p = 0. 007). No significant improvement was obtained for other subgroups.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- non-pulsatile tinnitus present > 1 year

- Tinnitus Handicap Questionnaire score > 30

- ability to perform psychophysical matching procedure

Exclusion Criteria:

- evidence of depression

- renal insufficiency

- conductive hearing loss

Locations and Contacts

Additional Information

Starting date: August 2003
Ending date: January 2005
Last updated: November 18, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012